Jayson L. Parker

1.2k total citations
34 papers, 967 citations indexed

About

Jayson L. Parker is a scholar working on Economics and Econometrics, Statistics and Probability and Immunology. According to data from OpenAlex, Jayson L. Parker has authored 34 papers receiving a total of 967 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Economics and Econometrics, 11 papers in Statistics and Probability and 8 papers in Immunology. Recurrent topics in Jayson L. Parker's work include Statistical Methods in Clinical Trials (11 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Biosimilars and Bioanalytical Methods (8 papers). Jayson L. Parker is often cited by papers focused on Statistical Methods in Clinical Trials (11 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Biosimilars and Bioanalytical Methods (8 papers). Jayson L. Parker collaborates with scholars based in Canada, United States and Brazil. Jayson L. Parker's co-authors include Constantine X. Poulos, Anh D. Lê, Sandra E. Black, John Paul Szalai, M. J. Bronskill, Christine A. Szekely, Gilberto Lopes, Jonathan O. Dostrovsky, Morris Moscovitch and Daphne Kidron and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and NeuroImage.

In The Last Decade

Jayson L. Parker

32 papers receiving 950 citations

Peers

Jayson L. Parker

CMN

PMH

PHYSI

Allitia DiBernardo United States

Stephen Flitman United States

Norman C. Moore United States

Steven Sevush United States

Cristian Carmeli Switzerland

Rayhan Lal United States

Mary F. Johnson United States

Tricia A. Thornton‐Wells United States

Jesen Fagerness United States

Lisa J. Strug Canada

Allitia DiBernardo United States

Jayson L. Parker

163 ×0.5

126 ×0.4

CMN

399 ×1.9

PMH

219 ×1.6

PHYSI

175 ×1.3

Citations per year, relative to Jayson L. Parker Jayson L. Parker (= 1×) peers Allitia DiBernardo

Countries citing papers authored by Jayson L. Parker

Since Specialization

Citations

This map shows the geographic impact of Jayson L. Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jayson L. Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jayson L. Parker more than expected).

Fields of papers citing papers by Jayson L. Parker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jayson L. Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jayson L. Parker. The network helps show where Jayson L. Parker may publish in the future.

Co-authorship network of co-authors of Jayson L. Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Jayson L. Parker. A scholar is included among the top collaborators of Jayson L. Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jayson L. Parker. Jayson L. Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parker, Jayson L., et al.. (2025). Agentic Medical Knowledge Graphs Enhance Medical Question Answering: Bridging the Gap Between LLMs and Evolving Medical Knowledge. 12682–12701.

Lopes, Gilberto, et al.. (2022). The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs. The Oncologist. 27(10). 849–856.

Parker, Jayson L., Stephen Mac, Gilberto Lopes, et al.. (2021). Does biomarker use in oncology improve clinical trial failure risk? A large‐scale analysis. Cancer Medicine. 10(6). 1955–1963. 24 indexed citations

Li, Alice, et al.. (2020). Clinical trial risk in leukemia: Biomarkers and trial design. Hematological Oncology. 39(1). 105–113. 5 indexed citations

Parker, Jayson L., et al.. (2015). Clinical Trial Risk in Chronic Obstructive Pulmonary Disease: The Effects of Drug Class and Inclusion Criteria. Respiration. 91(1). 79–86. 5 indexed citations

Parker, Jayson L., et al.. (2015). Reducing clinical trial risk in multiple sclerosis. Multiple Sclerosis and Related Disorders. 5. 81–88. 8 indexed citations

Silverberg, Jay, et al.. (2014). Clinical Trial Risk in Type-2 Diabetes: Importance of Patient History. Journal of Pharmacy & Pharmaceutical Sciences. 17(3). 393–393. 3 indexed citations

Lopes, Gilberto, et al.. (2014). Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(2). 163–169. 31 indexed citations

Chit, Ayman, et al.. (2013). Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines. Vaccine. 32(26). 3336–3340. 14 indexed citations

10.

Parker, Jayson L., et al.. (2012). Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Research and Treatment. 136(1). 179–185. 26 indexed citations

11.

Keystone, Edward, et al.. (2012). Risk of Failure of a Clinical Drug Trial in Patients with Moderate to Severe Rheumatoid Arthritis. The Journal of Rheumatology. 39(11). 2066–2070. 13 indexed citations

12.

Parker, Jayson L., et al.. (2011). Clinical Trial Risk in Non-Hodgkin’s Lymphoma: Endpoint and Target Selection. Journal of Pharmacy & Pharmaceutical Sciences. 14(2). 227–227. 17 indexed citations

13.

Parker, Jayson L. & Jillian Clare Köhler. (2010). The Success Rate of New Drug Development in Clinical Trials: Crohn’s Disease. Journal of Pharmacy & Pharmaceutical Sciences. 13(2). 191–191. 21 indexed citations

14.

Black, Sandra E., Scott D. Moffat, David C. Yu, et al.. (2000). Callosal Atrophy Correlates with Temporal Lobe Volume and Mental Status in Alzheimer's Disease. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 27(3). 204–209. 28 indexed citations

15.

Köhler, Stefan, Sandra E. Black, Christine A. Szekely, et al.. (1998). Memory impairments associated with hippocampal versus parahippocampal-gyrus atrophy: an MR volumetry study in Alzheimer’s disease. Neuropsychologia. 36(9). 901–914. 183 indexed citations

16.

Mathur, Anuradha, et al.. (1997). Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus. Brain Research. 775(1-2). 144–155. 58 indexed citations

17.

Kidron, Debora, Sandra E. Black, Peter Stanchev, et al.. (1997). Quantitative MR volumetry in Alzheimer's disease. Neurology. 49(6). 1504–1512. 93 indexed citations

18.

Poulos, Constantine X., Jayson L. Parker, & Anh D. Lê. (1996). Dexfenfluramine and 8-OH-DPAT modulate impulsivity in a delay-of-reward paradigm. Behavioural Pharmacology. 7(8). 395–395. 58 indexed citations

19.

Black, Sandra E., Christine A. Szekely, John Paul Szalai, et al.. (1996). Can MRI brain measures distinguish alzheimer's disease from normal aging?. NeuroImage. 3(3). S476–S476. 1 indexed citations

20.

Parker, Jayson L. & Derek van der Kooy. (1995). Tegmental pedunculopontine nucleus lesions do not block cocaine reward. Pharmacology Biochemistry and Behavior. 52(1). 77–83. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact